Peripheral nerve blocks: A tool for inpatient pediatric Status Migrainosus



      To assess the efficacy and safety of peripheral nerve blocks in the inpatient settings for pediatric patients presenting with status migrainosus.


      An analysis of a retrospective cohort of patients age range 13-18 years, admitted for status migrainosus from 2017 to 2022, was performed. Amongst the 1805 patients who presented with status migrainosus, 265 required hospital admission. A total of 177 patients failed the first- and second-line intravenous therapy and were treated with either peripheral nerve block (PNB) or dihydroergotamine (DHE) intravenous infusions. The primary outcome of the study was pain score level reduction by 50% and the secondary outcome was duration of hospital stay. A Visual Analogue Scale (VAS) score was used for pain assessment.


      Amongst the 177 patients, 100 patients were treated with DHE and 77 were treated with PNB. Target pain control was achieved in 59/100 in DHE patients and 38/77 amongst the PNB patients. The average hospital stay of patients who responded to PNB was significantly lower compared to patients receiving DHE (3.6 days vs 4.9 days). Among the 41 patients that were refractory to DHE, 30 patients received PNB, out of which 12 responded to nerve blocks. Most common side effect for PNBs were pain at injection site in 39% of patients and nausea/vomiting for DHE in 50% of patients.


      PNB can be safely administered in the hospital setting to pediatric patients with status migrainosus. PNB treatment helped achieve target pain control with minimal side effects and reduced the hospital stay duration.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Pediatric Neurology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Abu-Arafeh I.
        • Razak S.
        • Sivaraman B.
        • Graham C.
        Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies.
        Dev Med Child Neurol. 2010; 52: 1088-1097
      1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.
        Cephalalgia. 2018; 38: 1-211
        • Kedia S.
        • Ginde A.A.
        • Grubenhoff J.A.
        • Kempe A.
        • Hershey A.D.
        • Powers S.W.
        Monthly variation of United States pediatric headache emergency department visits.
        Cephalalgia. 2014; 34: 473-478
        • Friedman B.W.
        • Bijur P.E.
        • Lipton R.B.
        Standardizing emergency department–based migraine research: an analysis of commonly used clinical trial outcome measures.
        Acad. Emerg. Med. 2010; 17: 72-79
        • Theroux L.M.
        • Cappa R.
        • Mendoza A.
        • Mallawaarachchi I.
        • Samanta D.
        • Goodkin H.P.
        Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children.
        Headache. 2020; 60: 1653-1663
        • Srouji R.
        • Schenkel S.R.
        • Forbes P.
        • Cahill J.E.
        Dihydroergotamine infusion for pediatric refractory headache: A retrospective chart review.
        Headache. 2021; 61: 777-789
        • Cuadrado M.L.
        • Aledo-Serrano Á.
        • López-Ruiz P.
        • et al.
        Greater occipital nerve block for the acute treatment of prolonged or persistent migraine aura.
        Cephalalgia. 2017; 37: 812-818
        • Friedman B.W.
        • Mohamed S.
        • Robbins M.S.
        • et al.
        A Randomized, Sham-Controlled Trial of Bilateral Greater Occipital Nerve Blocks With Bupivacaine for Acute Migraine Patients Refractory to Standard Emergency Department Treatment With Metoclopramide.
        Headache. 2018; 58: 1427-1434
        • Korucu O.
        • Dagar S.
        • Çorbacioglu Ş.K.
        • Emektar E.
        • Cevik Y.
        The effectiveness of greater occipital nerve blockade in treating acute migraine-related headaches in emergency departments.
        Acta Neurol Scand. 2018; 138: 212-218
        • Allen S.M.
        • Mookadam F.
        • Cha S.S.
        • Freeman J.A.
        • Starling A.J.
        • Mookadam M.
        Greater Occipital Nerve Block for Acute Treatment of Migraine Headache: A Large Retrospective Cohort Study.
        J Am Board Fam Med. 2018; 31: 211-218
        • Ebied A.M.
        • Nguyen D.T.
        • Dang T.
        Evaluation of Occipital Nerve Blocks for Acute Pain Relief of Migraines.
        J Clin Pharmacol. 2020; 60: 378-383
        • Hokenek N.M.
        • Ozer D.
        • Yılmaz E.
        • et al.
        Comparison of greater occipital nerve and supra orbital nerve blocks methods in the treatment of acute migraine attack: A randomized double-blind controlled trial.
        Clin Neurol Neurosurg. 2021; 207106821
        • Chowdhury D.
        • Datta D.
        • Mundra A.
        Role of Greater Occipital Nerve Block in Headache Disorders: A Narrative Review.
        Neurol India. 2021; 69: S228-S256
        • Oswald J.C.
        • Schuster N.M.
        A randomized, double-dummy, emergency department-based study of greater occipital nerve block with bupivacaine versus intravenous metoclopramide for treatment of migraine: A comment.
        Headache. 2021; 61: 218
        • Gelfand A.A.
        • Reider A.C.
        • Goadsby P.J.
        Outcomes of greater occipital nerve injections in pediatric patients with chronic primary headache disorders.
        Pediatr Neurol. 2014; 50: 135-139
        • Renaudon-Smith E.
        • et al.
        Greater Occipital Nerve Injection (GONI) for chronic headache in children.
        Journal of Headache and Pain. 2010; : 76
        • Dubrovsky A.S.
        • Friedman D.
        • Kocilowicz H.
        Pediatric Post-Traumatic Headaches and Peripheral Nerve Blocks of the Scalp: A Case Series and Patient Satisfaction Survey.
        Headache. 2014; 54: 878-887
        • Seeger T.A.
        • et al.
        Occipital Nerve Blocks for Pediatric Posttraumatic Headache: A Case Series.
        J Child Neurol. 2015; 30: 1142-1146
        • Johr M.
        Regional anaesthesia in neonates, infants and children: an educational review.
        Eur J Anaesthesiol. 2015; 32: 289-297
        • Levin M.
        Nerve blocks in the treatment of headache.
        Neurotherapeutics. 2010; 7: 197-203
        • Afridi S.K.
        • Shields K.G.
        • Bhola R.
        • Goadsby P.J.
        Greater occipital nerve injection in primary headache syndromes--prolonged effects from a single injection.
        Pain. 2006; 122: 126-129
        • Law Huay-Zong
        • et al.
        “Hospital Burden of Migraine in United States Adults: A 15-year National Inpatient Sample Analysis.” Plastic and reconstructive surgery.
        Global open. 23 Apr. 2020; 8e2790
        • Nelson G.R.
        • Bale J.F.
        • Kerr L.M.
        Outcome and Cost of Inpatient Hospitalization for Intravenous Dihydroergotamine Treatment of Refractory Pediatric Headache.
        Pediatr Neurol. 2017 Jan; 66: 76-81
        • Tso A.R.
        • Patniyot I.R.
        • Gelfand A.A.
        • Goadsby P.J.
        Increase rate of venous thrombosis may be associated with inpatient dihydroergotamine treatment.
        Neurology. 2017; 89: 279-283
        • Diener H.C.
        • Dodick D.W.
        • Aurora S.K.
        • et al.
        OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
        Cephalalgia. 2010; 30: 804-814
        • Aurora S.K.
        • Dodick D.W.
        • Turkel C.C.
        • et al.
        OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
        Cephalalgia. 2010; 30: 793-803
        • Lewis D.W.
        • Winner P.
        • Wasiewski W.
        The placebo responder rate in children and adolescents.
        Headache. 2005; 45: 232-239